Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Trnava – page 11

389 clinical trials in Trnava, Slovakia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Trnava at a glance
389
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

389 trials in Trnava

Open in trial search

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Osteoporosis postmenopausal

Not yet recruiting

Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Curateq Biologics Private Limited

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+2

Not yet recruiting

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Laboratorios Farmaceuticos Rovi S.A.

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Type 2 diabetes mellitus

Not yet recruiting

Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Albiglutide
  • Sponsor:Eli Lilly & Co.

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Trnava

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for non-small cell lung cancer, advanced breast cancer, and head and neck cancer. Studies are evaluating new combination therapies and investigating targeted treatments for patients with specific biomarkers.

  • Metastatic breast cancer treatment evaluation
  • Lung cancer therapy combinations
  • Cancer cachexia management
02 Neurological Disorders

Multiple ongoing trials investigating treatments for relapsing multiple sclerosis. Research includes comparative studies of new therapeutic agents and evaluation of treatment effectiveness in patients transitioning between therapies.

  • MS disease modification
  • Comparative treatment efficacy
  • Novel therapeutic approaches
03 Cardiovascular Studies

Research focusing on atherosclerotic cardiovascular disease and stroke prevention. Trials are evaluating new treatments for reducing major cardiovascular events and managing complications in high-risk patients.

  • Stroke prevention strategies
  • Cardiovascular risk reduction
  • Atrial fibrillation management
04 Dermatological Conditions

Studies examining treatments for hidradenitis suppurativa, chronic plaque psoriasis, and vitiligo. Research includes both adult and pediatric populations, with a focus on novel therapeutic approaches.

  • Inflammatory skin conditions
  • Pediatric psoriasis treatment
  • Chronic skin disorder management
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.